Navigation Links
Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
Date:2/20/2008

for income taxes 119.7 127.1

Depreciation (includes accelerated

depreciation) 95.6 95.6

Amortization 80.8 80.8

EBITDA 507.0 527.0

Adjusted for:

Global supply chain initiative 23.4 23.4

Share-based compensation 16.7 16.7

Licensing charges 6.0 6.0

Loss on early extinguishment of debt 1.9 1.9

Adjusted EBITDA $555.0 $575.0

The reconciliation table is based in part on management's estimate of adjusted EBITDA for the year ending December 31, 2008. Watson expects certain known GAAP charges for 2008, as presented in the schedule above. Other GAAP charges that may be excluded from estimated EBITDA are possible, but their amounts are dependent on numerous factors that we currently cannot ascertain with sufficient certainty or are presently unknown. These GAAP charges, such as potential asset impairment charges, are dependent upon future events and valuations that have not yet been performed.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Watson Receives FDA Approval for Generic Accuneb(R)
4. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
5. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
6. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
7. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
8. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Selexis SA, a serial ... Cell Banks (RCBs) used for drug discovery to commercial ... will include Next-Generation Sequencing (NGS) data packages. ... biologic manufacturing by ensuring the integrity of the gene, ...
(Date:1/22/2015)... , 22 de enero de 2015  El Dr. ... su llamada a nominaciones para 2015. Este prestigioso premio ... o tiene el potencial para hacer, contribuciones destacadas para ... aceptarán hasta el 15 de marzo de 2015 a ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... has been honored for its commitment to sustainability with inclusion ... Varian is the highest ranked healthcare equipment company among the ... during the World Economic Forum at Davos, Switzerland ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... met its primary endpoint of non-inferiority to Pegasys (peginterferon alfa-2a) ... and 3 chronic hepatitis C - , ... comparable rates of serious adverse events, severe adverse events and ... , ROCKVILLE, Md., Dec. 8 ...
... ATSI ), manufacturer and marketer of state-of-the-art cardiac surgery,products ... the,marketing of the ATS 3f(R) Aortic Bioprosthesis that includes a ... device. , (Logo: ... While the ATS 3f Aortic Bioprosthesis PMA was approved on ...
... databases enable researchers to quickly and effectively use these invaluable resources. ... ... OpenHelix today announced the availability of an updated suite ... Textpresso. Gene Ontology is a consortium project developed to ...
Cached Biology Technology:Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 2Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 3Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 4Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 5Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 6Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 7Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 8Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 9ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 2ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 3New and Updated Online Tutorials for Textpresso and Gene Ontology 2
(Date:12/17/2014)... is fundamentally transforming the travel experience and nowhere is ... past decade, ePassports, biometric readers, and secure document scanners ... control via eGates and Automated Passport Control (APC) Kiosks ... borders across the globe. According to ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... to their offering. One major trend ... biometric systems. Multimodal biometric systems utilize more than one ...
(Date:12/10/2014)... You,ve been here before: you desperately need to sign into ... or the answer to your secret question. What,s your dog,s birthday? ... Hoyos Labs , a digital infrastructure security company, launches the ... that comes with usernames, passwords and PINs – 1U TM ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... Calif.) Researchers at the UC Davis M.I.N.D. Institute and ... to date describing the medical and psychological characteristics of a ... two "Y" chromosomes, rather than the normal one of each. ... the American Journal of Medical Genetics Part A, ...
... that there is more than one way to grow a biofilm, ... product claims it kills "99 percent" of bacteria, it really does ... bacteria that form on most wet surfaces. They range from the ... sludge that clogs pipes. Most biofilms are harmless, but ...
... available in German . , Together with ... the Center for Allergy and Environment of the Technische ... pinpointed a major gene for allergic diseases. The gene ... whole human genome at the Helmholtz Zentrum Mnchen. The ...
Cached Biology News:UC Davis researchers define characteristics, treatment options for XXYY syndrome 2UC Davis researchers define characteristics, treatment options for XXYY syndrome 3MSU biofilms research helps set standards for everyday products 2Munich researchers discover key allergy gene 2
...
...
... the rapid isolation of DNA from high melt ... the spin filter, centrifuge for 3 minutes, and ... is no need to melt agarose or use ... be used for buffer exchange, primer removal from ...
ChemiArray Human Cytokine Antibody Array VII, 60 cytokines per membrane...
Biology Products: